Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05881798 · ClinicalTrials.gov registry record

Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study

A clinical trial, sponsored by Cook Research Incorporated.

Recruiting
Registry status
82
Enrollment target

NCT05881798: Recruiting study, sponsored by Cook Research Incorporated.

NCT05881798 is a clinical trial that is actively recruiting participants, run by Cook Research Incorporated. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05881798 is actively recruiting participants, sponsored by Cook Research Incorporated.

RECRUITING
Registry status
82 participants
Enrollment target

Study Summary

This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and continued acceptability of the benefit:risk ratio. Additionally, the study intends to evaluate longer-term (i.e., up to 5 years) outcome data while the filter is indwelling.

Primary Outcome

Freedom from major adverse events through 12 months (365 ± 30 days), defined as clinically significant IVC penetration, migration of filter (\>2 cm)/filter components, filter fracture, embolization of filter or filter fragments to the heart or lungs, IVC thrombotic occlusion, symptomatic deep vein thrombosis while a filter is indwelling, access site complications with clinical sequelae, and procedure/device-related death.

Interventions

  • DEVICE Celect Platinum Vena Cava Filter

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2025-06-02
Est. Completion 2030-12
Cook Research Incorporated

24 total trials

What NCT05881798 shows while recruiting

NCT05881798 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Celect Platinum Vena Cava Filter is the first listed.

NCT05881798 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05881798 about?

NCT05881798 is a clinical study titled "Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study". This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and performance of the devices throughout their expected lifetime and conti...

What is the current status of trial NCT05881798?

This trial is currently recruiting. The enrollment target is 82 participants. The study started on 2025-06-02. Estimated completion is 2030-12.

What interventions are being tested in trial NCT05881798?

The interventions under investigation include: Celect Platinum Vena Cava Filter (DEVICE).

Who is sponsoring clinical trial NCT05881798?

This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03319901 · 82 participants · Phase 1

    Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

  • NCT03493425 · 82 participants · Phase 2

    Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

  • NCT04105270 · 82 participants · Phase 2

    RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

  • NCT04428658 · 82 participants · NA

    Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05881798, the US trial registry maintained by the National Library of Medicine. NCT05881798 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.